http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0337774-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d43e14df43b1f0c6412df715f82d3ced |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-06156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0821 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-078 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-403 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-405 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K5-097 |
| filingDate | 1989-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_246a128da096926761b0ad008aae1452 |
| publicationDate | 1989-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0337774-A2 |
| titleOfInvention | CCK antagonists |
| abstract | Cholecystokinin (CCK) antagonists are described of the formula:n or a pharmaceutically acceptable salt thereof, wherein each R 1 is, independently, an alkyl group having 1-5, inclusive, carbon atoms, an alkoxy group having 1-5, inclusive, carbon atoms, a halogen, amino, hydroxy, nitro, cyano, carboxyl, trifluoreo- methyl, ethyl carboxylate, or a hydrogen; m is an integer between 0 and 2, inclusive,; and A is eithern vhere n is an integer between 1 and 5, inclusive, and R 2 is hydroxy, an alkoxy group having 1-5, inclusive, carbon atoms, aralkoxy, aralkyl, amino, an alkyl group having 1-5, inclusive, carbon atoms, an alkylamino group having 1-5, inclusive, carbon atoms, a dialkylamino group with each alkyl group, independently having 1-5, inclusive, carbon atoms, a cycloalkylamino group wherein the ring has 4-6, inclusive, carbon atoms, or morpholino; or A is an alkyl group having 1-5, inclusive, carbon atoms, a hydroxyalkyl group having 1-5, inclusive, carbon atoms, an alkoxyalkyl group having 2-8, inclusive, carbon atoms, an aralkoxyalkyl having 8-14, inclusive, carbon atoms, an aryl group having 6-14, inclusive, carbon atoms, an aralkyl group having 6-14, inclusive, carbon atoms, and a cycloalkyl group having 3-12, inclusive, carbon atoms. n CCK antagonists are also described of the formula:n or pharmaceutically acceptable salt thereof, wherein m is an integer between 0 and 2, inclusive; A is eithern wherein n is an integer between 1 and 5, inclusive, and R 2 is hydroxy, an alkoxy group having 1-5, inclusive, carbon atoms, aralkoxy, aralkyl, amino, an alkyl group having 1-5, inclusive, carbon atoms, an alkylamino group having 1-5, inclusive, carbon atoms, a dialkylamino group with each alkyl group having 1-5, inclusive, carbon atoms, a cycloalkylamino group wherein the ring has 4-6, inclusive, carbon atoms, or morpholino; or A is an alkyl group having 1-5, inclusive, carbon atoms, a hydroxalkyl group having 1-5, inclusive, carbon atoms, an alkoxyalkyl group group having 2-8, inclusive, carbon atoms, an aralkoxyalkyl having 8-14, inclusive, carbon atoms, an aryl group having 6-14, inclusive, carbon atoms, an aralkyl group having 6-14, inclusive, carbon atoms, or a cycloalkyl group having 3-12, inclusive, carbon atoms. n Use is described of these antagonists for the treatment of disorders such as gastric, peptic or duodenal ulcers, or acute pancreatitis and for the suppression of appetite. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9113874-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9504720-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1904468-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9320099-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1904468-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5780498-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9320099-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2659966-A1 |
| priorityDate | 1988-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 170.